{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T07:06:20Z","timestamp":1783062380826,"version":"3.54.6"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s00520-021-06061-8","type":"journal-article","created":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T23:47:00Z","timestamp":1613692020000},"page":"5029-5035","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy of one-day versus multiple-day dexamethasone for chemotherapy-induced nausea and vomiting in lung cancer patients receiving carboplatin-based chemotherapy: a propensity score\u2013matched analysis"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6183-4939","authenticated-orcid":false,"given":"Toshinobu","family":"Hayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mototsugu","family":"Shimokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumitaka","family":"Mizuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Kawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Egawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,16]]},"reference":[{"key":"6061_CR1","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00520-016-3365-1","volume":"25","author":"F Roila","year":"2017","unstructured":"Roila F, Warr D, Hesketh PJ, Gralla R, Herrstedt J, Jordan K, Aapro M, Ballatori E, Rapoport B (2017) 2016 Updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following moderately emetogenic chemotherapy. Support Care Cancer 25:289\u2013294. https:\/\/doi.org\/10.1007\/s00520-016-3365-1","journal-title":"Support Care Cancer"},{"key":"6061_CR2","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Lyman GH (2020) Antiemetics: ASCO Guideline update. J Clin Oncol 38:2782\u20132797. https:\/\/doi.org\/10.1200\/JCO.20.01296","journal-title":"J Clin Oncol"},{"key":"6061_CR3","unstructured":"NCCN clinical practice guidelines in oncology (2020) Antiemetics. version 2, vol. 2020. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf. Accessed 20 Oct 2020"},{"key":"6061_CR4","doi-asserted-by":"publisher","unstructured":"Aogi K, Takeuchi H, Saeki T, Aiba K, Tamura K, Iino K, Imamura CK, Okita K, Kagami Y, Tanaka R, Nakagawa K, Fujii H, Boku N, Wada M, Akechi T, Iihara H, Ohtani S, Okuyama A, Ozawa K, Kim YI, Sasaki H, Shima Y, Takeda M, Nagasaki E, Nishidate T, Higashi T, Hirata K (2020) Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis. Int J Clin Oncol published online 08 November 2020. https:\/\/doi.org\/10.1007\/s10147-020-01818-3","DOI":"10.1007\/s10147-020-01818-3"},{"key":"6061_CR5","doi-asserted-by":"publisher","first-page":"e373","DOI":"10.1634\/theoncologist.2019-0292","volume":"25","author":"H Iihara","year":"2020","unstructured":"Iihara H, Shimokawa M, Hayashi T, Kawazoe H, Saeki T, Aiba K, Tamura K (2020) A nationwide, multicenter registry study of antiemesis for carboplatin-based chemotherapy-induced nausea and vomiting in Japan. Oncologist 25:e373\u2013e380. https:\/\/doi.org\/10.1634\/theoncologist.2019-0292","journal-title":"Oncologist"},{"key":"6061_CR6","doi-asserted-by":"publisher","first-page":"225","DOI":"10.21873\/anticanres.13101","volume":"39","author":"M Shimokawa","year":"2019","unstructured":"Shimokawa M, Hayashi T, Kogawa T, Matsui R, Mizuno M, Kikkawa F, Saeki T, Aiba K, Tamura K (2019) Evaluation of combination antiemetic therapy on CINV in patients with gynecologic cancer receiving TC chemotherapy. Anticancer Res 39:225\u2013230. https:\/\/doi.org\/10.21873\/anticanres.13101","journal-title":"Anticancer Res"},{"key":"6061_CR7","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.lungcan.2014.03.017","volume":"84","author":"Y Ito","year":"2014","unstructured":"Ito Y, Karayama M, Inui N, Kuroishi S, Nakano H, Nakamura Y, Yokomura K, Toyoshima M, Shirai T, Masuda M, Yamada T, Yasuda K, Hayakawa H, Suda T, Chida K (2014) Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy. Lung Cancer 84:259\u2013264. https:\/\/doi.org\/10.1016\/j.lungcan.2014.03.017","journal-title":"Lung Cancer"},{"key":"6061_CR8","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s12032-018-1199-z","volume":"35","author":"M Karayama","year":"2018","unstructured":"Karayama M, Inui N, Tanaka K, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Suda T (2018) Prophylactic aprepitant is better than salvage for carboplatin-based chemotherapy: a propensity score-matched analysis. Med Oncol 35:139. https:\/\/doi.org\/10.1007\/s12032-018-1199-z","journal-title":"Med Oncol"},{"key":"6061_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00520-017-3857-7","volume":"26","author":"K Jordan","year":"2018","unstructured":"Jordan K, Bl\u00e4ttermann L, Hinke A, M\u00fcller-Tidow C, Jahn F (2018) Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy?-a systematic review and meta-analysis. Support Care Cancer 26:21\u201332. https:\/\/doi.org\/10.1007\/s00520-017-3857-7","journal-title":"Support Care Cancer"},{"key":"6061_CR10","doi-asserted-by":"publisher","first-page":"493","DOI":"10.6004\/jnccn.2012.0049","volume":"10","author":"SY Barbour","year":"2012","unstructured":"Barbour SY (2012) Corticosteroids in the treatment of chemotherapy-induced nausea and vomiting. J Natl Compr Canc Netw 10:493\u2013499. https:\/\/doi.org\/10.6004\/jnccn.2012.0049","journal-title":"J Natl Compr Canc Netw"},{"key":"6061_CR11","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/sj.bjc.6603048","volume":"94","author":"J Vardy","year":"2006","unstructured":"Vardy J, Chiew KS, Galica J, Pond GR, Tannock IF (2006) Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 94:1011\u20131015. https:\/\/doi.org\/10.1038\/sj.bjc.6603048","journal-title":"Br J Cancer"},{"key":"6061_CR12","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1177\/0091270004264641","volume":"44","author":"R Stoltz","year":"2004","unstructured":"Stoltz R, Cyong JC, Shah A, Parisi S (2004) Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects. J Clin Pharmacol 44:520\u2013531. https:\/\/doi.org\/10.1177\/0091270004264641","journal-title":"J Clin Pharmacol"},{"key":"6061_CR13","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ejphar.2009.10.002","volume":"626","author":"C Rojas","year":"2010","unstructured":"Rojas C, Thomas AG, Alt J, Stathis M, Zhang J, Rubenstein EB, Sebastiani S, Cantoreggi S, Slusher BS (2010) Palonosetron triggers 5-HT3 receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol 626:193\u2013199. https:\/\/doi.org\/10.1016\/j.ejphar.2009.10.002","journal-title":"Eur J Pharmacol"},{"key":"6061_CR14","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1093\/annonc\/mdp584","volume":"21","author":"M Aapro","year":"2010","unstructured":"Aapro M, Fabi A, Nol\u00e8 F, Medici M, Steger G, Bachmann C, Roncoroni S, Roila F (2010) Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol 21:1083\u20131088. https:\/\/doi.org\/10.1093\/annonc\/mdp584","journal-title":"Ann Oncol"},{"key":"6061_CR15","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/cas.12675","volume":"106","author":"Y Komatsu","year":"2015","unstructured":"Komatsu Y, Okita K, Yuki S, Furuhata T, Fukushima H, Masuko H, Kawamoto Y, Isobe H, Miyagishima T, Sasaki K, Nakamura M, Ohsaki Y, Nakajima J, Tateyama M, Eto K, Minami S, Yokoyama R, Iwanaga I, Shibuya H, Kudo M, Oba K, Takahashi Y (2015) Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with palonosetron. Cancer Sci 106:891\u2013895. https:\/\/doi.org\/10.1111\/cas.12675","journal-title":"Cancer Sci"},{"key":"6061_CR16","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s00520-010-0941-7","volume":"19","author":"L Celio","year":"2011","unstructured":"Celio L, Frustaci S, Denaro A, Buonadonna A, Ardizzoia A, Piazza E, Fabi A, Capobianco AM, Isa L, Cavanna L, Bertolini A, Bichisao E, Bajetta E (2011) Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial. Support Care Cancer 19:1217\u20131225. https:\/\/doi.org\/10.1007\/s00520-010-0941-7","journal-title":"Support Care Cancer"},{"key":"6061_CR17","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1007\/s00520-015-2760-3","volume":"23","author":"N Furukawa","year":"2015","unstructured":"Furukawa N, Kanayama S, Tanase Y, Ito F (2015) Palonosetron in combination with 1-day versus 3-day dexamethasone to prevent nausea and vomiting in patients receiving paclitaxel and carboplatin. Support Care Cancer 23:3317\u20133322. https:\/\/doi.org\/10.1007\/s00520-015-2760-3","journal-title":"Support Care Cancer"},{"key":"6061_CR18","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s00520-015-2905-4","volume":"24","author":"Y Kosaka","year":"2016","unstructured":"Kosaka Y, Tanino H, Sengoku N, Minatani N, Kikuchi M, Nishimiya H, Waraya M, Katoh H, Enomoto T, Sato T, Kuranami M, Watanabe M (2016) Phase II randomized, controlled trial of 1 day versus 3 days of dexamethasone combined with palonosetron and aprepitant to prevent nausea and vomiting in Japanese breast cancer patients receiving anthracycline-based chemotherapy. Support Care Cancer 24:1405\u20131411. https:\/\/doi.org\/10.1007\/s00520-015-2905-4","journal-title":"Support Care Cancer"},{"key":"6061_CR19","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1634\/theoncologist.2019-0133","volume":"24","author":"Y Okada","year":"2019","unstructured":"Okada Y, Oba K, Furukawa N, Kosaka Y, Okita K, Yuki S, Komatsu Y, Celio L, Aapro M (2019) One-day versus three-day dexamethasone in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a systematic review and individual patient data-based meta-analysis. Oncologist 24:1593\u20131600. https:\/\/doi.org\/10.1634\/theoncologist.2019-0133","journal-title":"Oncologist"},{"key":"6061_CR20","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1186\/s12885-019-6454-y","volume":"19","author":"L Celio","year":"2019","unstructured":"Celio L, Bonizzoni E, Zattarin E, Codega P, de Braud F, Aapro M (2019) Impact of dexamethasone-sparing regimens on delayed nausea caused by moderately or highly emetogenic chemotherapy: a meta-analysis of randomised evidence. BMC Cancer 19:1268. https:\/\/doi.org\/10.1186\/s12885-019-6454-y","journal-title":"BMC Cancer"},{"key":"6061_CR21","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1200\/JCO.2017.74.4375","volume":"36","author":"Y Ito","year":"2018","unstructured":"Ito Y, Tsuda T, Minatogawa H, Kano S, Sakamaki K, Ando M, Tsugawa K, Kojima Y, Furuya N, Matsuzaki K, Fukuda M, Sugae S, Ohta I, Arioka H, Tokuda Y, Narui K, Tsuboya A, Suda T, Morita S, Boku N, Yamanaka T, Nakajima TE (2018) Placebo-controlled, double-blinded phase III study comparing dexamethasone on day 1 with dexamethasone on days 1 to 3 with combined neurokinin-1 receptor antagonist and palonosetron in high-emetogenic chemotherapy. J Clin Oncol 36:1000\u20131006. https:\/\/doi.org\/10.1200\/JCO.2017.74.4375","journal-title":"J Clin Oncol"},{"key":"6061_CR22","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s10147-015-0786-7","volume":"20","author":"K Tamura","year":"2015","unstructured":"Tamura K, Aiba K, Saeki T, Nakanishi Y, Kamura T, Baba H, Yoshida K, Yamamoto N, Kitagawa Y, Maehara Y, Shimokawa M, Hirata K, Kitajima M, CINV Study group of Japan (2015) Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan. Int J Clin Oncol 20:855\u2013865. https:\/\/doi.org\/10.1007\/s10147-015-0786-7","journal-title":"Int J Clin Oncol"},{"key":"6061_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM199501053320101","volume":"1","author":"Italian Group for Antiemetic, Research","year":"1995","unstructured":"Italian Group for Antiemetic, Research (1995) Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 1:1\u20135. https:\/\/doi.org\/10.1056\/NEJM199501053320101","journal-title":"N Engl J Med"},{"key":"6061_CR24","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.2147\/cmar.S176574","volume":"10","author":"T Hayashi","year":"2018","unstructured":"Hayashi T, Shimokawa M, Matsuo K, Miyoshi T, Toriyama Y, Yokota C, Taniguchi J, Hanada K, Tsumagari K, Okubo N, Koutake Y, Sakata K, Kawamata Y, Goto T, Tsurusaki Y, Koyabu M (2018) Risk factors for delayed chemotherapy-induced nausea and vomiting with low-emetic-risk chemotherapy: a prospective, observational, multicenter study. Cancer Manag Res 10:4249\u20134255. https:\/\/doi.org\/10.2147\/cmar.S176574","journal-title":"Cancer Manag Res"},{"key":"6061_CR25","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1515725","volume":"375","author":"RM Navari","year":"2016","unstructured":"Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, Dietrich L, Biggs D, Lafky JM, Loprinzi CL (2016) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 375:134\u2013142. https:\/\/doi.org\/10.1056\/NEJMoa1515725","journal-title":"N Engl J Med"},{"key":"6061_CR26","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S1470-2045(19)30678-3","volume":"21","author":"H Hashimoto","year":"2020","unstructured":"Hashimoto H, Abe M, Tokuyama O, Mizutani H, Uchitomi Y, Yamaguchi T, Hoshina Y, Sakata Y, Takahashi TY, Nakashima K, Nakao M, Takei D, Zenda S, Mizukami K, Iwasa S, Sakurai M, Yamamoto N, Ohe Y (2020) Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21:242\u2013249. https:\/\/doi.org\/10.1016\/S1470-2045(19)30678-3","journal-title":"Lancet Oncol"},{"key":"6061_CR27","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00280-019-03868-5","volume":"84","author":"K Tanaka","year":"2019","unstructured":"Tanaka K, Inui N, Karayama M, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Kusagaya H, Matsuura S, Uto T, Hashimoto D, Matsui T, Asada K, Suda T (2019) Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting. Cancer Chemother Pharmacol 84:147\u2013153. https:\/\/doi.org\/10.1007\/s00280-019-03868-5","journal-title":"Cancer Chemother Pharmacol"},{"key":"6061_CR28","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1007\/s00520-012-1710-6","volume":"21","author":"RM Navari","year":"2013","unstructured":"Navari RM, Nagy CK, Gary SE (2013) The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 21:1655\u20131663. https:\/\/doi.org\/10.1007\/s00520-012-1710-6","journal-title":"Support Care Cancer"},{"key":"6061_CR29","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1634\/theoncologist.2016-0308","volume":"22","author":"M Nakamura","year":"2017","unstructured":"Nakamura M, Ishiguro A, Muranaka T, Fukushima H, Yuki S, Ono K, Murai T, Matsuda C, Oba A, Itaya K, Sone T, Yagisawa M, Koike Y, Endo A, Tsukuda Y, Ono Y, Kudo T, Nagasaka A, Nishikawa S, Komatsu Y (2017) A prospective observational study on effect of short-term periodic steroid premedication on bone metabolism in gastrointestinal cancer (ESPRESSO-01). Oncologist 22:592\u2013600. https:\/\/doi.org\/10.1634\/theoncologist.2016-0308","journal-title":"Oncologist"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06061-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-021-06061-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06061-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T10:17:50Z","timestamp":1626862670000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-021-06061-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,16]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["6061"],"URL":"https:\/\/doi.org\/10.1007\/s00520-021-06061-8","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,16]]},"assertion":[{"value":"8 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"N\/A","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}